Joint Formulary & PAD

Solriamfetol - Narcolepsy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Associated Icons :
BNF SPC
CD
ICB
NICE
Restrictions / Comments :
Important
QVH = local sleep specialist centre

PAD Profile

ChemicalSubstance :
Solriamfetol
Indication :
Narcolepsy
Group Name :
Keywords :
Excessive sleepiness, fatigue
Brand Names Include :
Sunosi
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Solriamfetol is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Narcolepsy.

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends solriamfetol as a treatment option in the treatment of excessive daytime sleepiness caused by narcolepsy (NICE TA758)

Solriamfetol will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA758.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.